Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
ScandiDos AB is a notable company specializing in advanced radiation therapy solutions for cancer treatment facilities. Primarily focused on improving the precision and effectiveness of radiation therapy, ScandiDos develops state-of-the-art quality assurance systems. Its flagship product, Delta4 Phantom+, is widely recognized for its ability to enhance the accuracy of dose delivery in radiotherapy, making critical contributions to patient safety and treatment outcomes. Beyond this, ScandiDos offers services that integrate seamlessly with existing systems in clinics, ensuring effective implementation and operation. Servicing the healthcare sector, particularly oncology departments, ScandiDos AB plays a vital role in advancing cancer treatment technologies. Based in Sweden, the company's innovations are helping to set new standards in medical equipment, influencing both clinical practices and the broader medical device industry. By providing cutting-edge technology and support, ScandiDos AB is instrumental in the ongoing evolution and improvement of cancer treatment methodologies across global markets.
kr 0.05
+kr 0.00 (+4.44%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-5.51% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 12.3% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -kr 7M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 54M
▼ -12.3% YoY
Net Income (TTM)
-kr 3M
▼ -1150.5% YoY
Op. Margin
-5.51%
▲ +16.3pp YoY
ROIC
-5.45%
▲ +18.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 7M
▲ +27.9% YoY
Op. Cash Flow (TTM)
-kr 5M
▲ +47.4% YoY
Net Debt
-kr 4M
Net Cash Position
Cash & Equiv.
kr 4M
3Y CAGR: -4.1%
Continue Research
ScandiDos AB (SDOS.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, ScandiDos AB scores 25/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
ScandiDos AB scores 25 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -5.5% operating margin and a -5.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SDOS.XSTO's valuation and scores 25/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.